Vanguard Group’s Myovant Sciences Ltd. MYOV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-831,250
| Closed | -$22.4M | – | 4606 |
|
|
2022
Q4 | $22.4M | Buy |
831,250
+9,409
| +1% | +$247K | ﹤0.01% | 2569 |
|
|
2022
Q3 | $14.8M | Sell |
821,841
-37,314
| -4% | -$596K | ﹤0.01% | 2761 |
|
|
2022
Q2 | $10.7M | Buy |
859,155
+76,118
| +10% | +$840K | ﹤0.01% | 2957 |
|
|
2022
Q1 | $10.4M | Sell |
783,037
-5,123
| -0.6% | -$68.7K | ﹤0.01% | 3122 |
|
|
2021
Q4 | $12.3M | Sell |
788,160
-12,385
| -2% | -$236K | ﹤0.01% | 3110 |
|
|
2021
Q3 | $18M | Buy |
800,545
+26,228
| +3% | +$576K | ﹤0.01% | 2922 |
|
|
2021
Q2 | $17.6M | Buy |
774,317
+15,738
| +2% | +$331K | ﹤0.01% | 2914 |
|
|
2021
Q1 | $15.6M | Buy |
758,579
+610,261
| +411% | +$13.9M | ﹤0.01% | 2922 |
|
|
2020
Q4 | $4.1M | Sell |
148,318
-68,145
| -31% | -$1.33M | ﹤0.01% | 3444 |
|
|
2020
Q3 | $3.04M | Buy |
216,463
+74,155
| +52% | +$1.38M | ﹤0.01% | 3359 |
|
|
2020
Q2 | $2.93M | Buy |
142,308
+7,111
| +5% | +$96.7K | ﹤0.01% | 3319 |
|
|
2020
Q1 | $1.02M | Buy |
135,197
+4,829
| +4% | +$54.2K | ﹤0.01% | 3485 |
|
|
2019
Q4 | $2.02M | Buy |
130,368
+8,796
| +7% | +$88.7K | ﹤0.01% | 3447 |
|
|
2019
Q3 | $632K | Sell |
121,572
-2,184
| -2% | -$16.2K | ﹤0.01% | 3764 |
|
|
2019
Q2 | $1.12M | Buy |
+123,756
| New | +$1.85M | ﹤0.01% | 3641 |
|
|
2017
Q2 | – | Sell |
-29,958
| Closed | -$352K | – | 4088 |
|
|
2017
Q1 | $352K | Buy |
29,958
+1,440
| +5% | +$16.5K | ﹤0.01% | 3811 |
|
|
2016
Q4 | $354K | Buy |
+28,518
| New | +$330K | ﹤0.01% | 3798 |
|
Other funds holding MYOV
Vanguard Group's MYOV Position: Q1 2023 in Review
Vanguard Group sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 831,250 shares — an estimated $22.4M sold.
Vanguard Group first reported a position in MYOV in Q4 2016 and held it in 17 quarters. The position peaked at $22.4M in Q4 2022. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.
- Vanguard Group reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
- Vanguard Group sold 831,250 Myovant Sciences Ltd. shares in Q1 2023, an estimated $22.4M.
- Vanguard Group first reported a position in Myovant Sciences Ltd. in Q4 2016 and held it in 17 quarters.
- Vanguard Group's Myovant Sciences Ltd. position peaked at $22.4M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.
Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.